The concept of the engineered anti-HER2 macrophage-drug conjugate (HMC) strategy and its anti-tumor effect were validated, which provide an inherent tumor-oriented tendency and intrinsic biotherapeutic function for effective targeting and therapy of tumors. The gene discussed is ERBB2; the disease is neoplasm.